JP2022526292A5 - - Google Patents

Info

Publication number
JP2022526292A5
JP2022526292A5 JP2021556435A JP2021556435A JP2022526292A5 JP 2022526292 A5 JP2022526292 A5 JP 2022526292A5 JP 2021556435 A JP2021556435 A JP 2021556435A JP 2021556435 A JP2021556435 A JP 2021556435A JP 2022526292 A5 JP2022526292 A5 JP 2022526292A5
Authority
JP
Japan
Prior art keywords
liquid pharmaceutical
stable liquid
pharmaceutical formulation
formulation according
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526292A (ja
JP7695887B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023795 external-priority patent/WO2020191270A1/en
Publication of JP2022526292A publication Critical patent/JP2022526292A/ja
Publication of JP2022526292A5 publication Critical patent/JP2022526292A5/ja
Priority to JP2025094518A priority Critical patent/JP2025131756A/ja
Application granted granted Critical
Publication of JP7695887B2 publication Critical patent/JP7695887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556435A 2019-03-21 2020-03-20 抗ｉｌ－３３抗体を含有する安定化製剤 Active JP7695887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025094518A JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821661P 2019-03-21 2019-03-21
US62/821,661 2019-03-21
PCT/US2020/023795 WO2020191270A1 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-il-33 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025094518A Division JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Publications (3)

Publication Number Publication Date
JP2022526292A JP2022526292A (ja) 2022-05-24
JP2022526292A5 true JP2022526292A5 (https=) 2023-03-24
JP7695887B2 JP7695887B2 (ja) 2025-06-19

Family

ID=70228884

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556435A Active JP7695887B2 (ja) 2019-03-21 2020-03-20 抗ｉｌ－３３抗体を含有する安定化製剤
JP2025094518A Pending JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025094518A Pending JP2025131756A (ja) 2019-03-21 2025-06-06 抗ｉｌ－３３抗体を含有する安定化製剤

Country Status (19)

Country Link
US (2) US11596690B2 (https=)
EP (1) EP3941522A1 (https=)
JP (2) JP7695887B2 (https=)
KR (1) KR20210141592A (https=)
CN (3) CN119700966A (https=)
AU (1) AU2020241882A1 (https=)
BR (1) BR112021018727A2 (https=)
CA (1) CA3133995A1 (https=)
CL (1) CL2021002440A1 (https=)
CO (1) CO2021011648A2 (https=)
EA (1) EA202192568A1 (https=)
IL (2) IL286024B2 (https=)
MA (1) MA55362A (https=)
MX (1) MX2021011137A (https=)
PH (1) PH12021552092A1 (https=)
SA (1) SA521430229B1 (https=)
SG (1) SG11202109822XA (https=)
TW (2) TW202519263A (https=)
WO (1) WO2020191270A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
JP7804590B2 (ja) * 2020-05-11 2026-01-22 メディミューン リミテッド 抗ｉｌ－３３抗体の処方物
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023077685A1 (zh) * 2021-11-04 2023-05-11 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的浓缩溶液的制备方法及液体制剂
CN113842457B (zh) * 2021-11-04 2022-05-20 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的液体制剂
WO2026067832A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗il-33单域抗体及其衍生物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
ATE414151T1 (de) * 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0600351D0 (en) * 2006-01-10 2006-02-15 Weston Terence E Safe hypodermic needle
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
WO2008144610A1 (en) 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2013059524A2 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
PT3889181T (pt) * 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA201890891A1 (ru) 2015-10-06 2018-09-28 Ридженерон Фармасьютикалз, Инк. Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MY197202A (en) * 2017-03-16 2023-05-31 Lg Chemical Ltd A liquid formulation of anti-tnf alpha antibody
US20240124889A1 (en) * 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN112851814B (zh) * 2020-03-17 2023-07-07 西安宇繁生物科技有限责任公司 一种靶向bcma的全人源单链抗体及其制备方法与应用
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法

Similar Documents

Publication Publication Date Title
CN106267189B (zh) 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
JP2022526292A5 (https=)
KR102667484B1 (ko) 안정한 항체 제형
CN103108656B (zh) 含有抗ngf抗体的稳定化制剂
JP2016020371A (ja) 抗インターロイキン６受容体（ｉｌ−６ｒ）抗体を含有する安定化製剤
JP2023511080A (ja) 安定な抗体製剤
CA2872275A1 (en) Stabilized formulations containing anti-dll4 antibodies
WO2025096478A1 (en) Stable antibody formulation comprising fianlimab
TWI498121B (zh) 含有抗－介白素－４受體（ｉｌ－４ｒ）抗體之安定化配製物
JP2023533963A5 (https=)
HK1232793A1 (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2024135750A (ru) Составы антитела к рецептору интерлейкина-4 (il-4r)
HK40039744A (en) Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HK1232793B (zh) 含有抗白介素-4 受体(il-4r)的抗体的稳定制剂
EA042167B1 (ru) Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r)